Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 235-043-6 | CAS number: 12060-58-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable, well documented publication which meets basic scientific principles.
Data source
Reference
- Reference Type:
- publication
- Title:
- Systemic lanthanum is excreted in the bile of rats
- Author:
- Damment S.J.P. and Pennick M.
- Year:
- 2 007
- Bibliographic source:
- Toxicology Letters 171: 69-77
Materials and methods
- Objective of study:
- toxicokinetics
- Principles of method if other than guideline:
- Lanthanum chloride was administered by intravenous injection in rats and the plasma lanthanum concentration was determined (two independent experiments with different single doses).
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Lanthanum chloride, anhydrous
- EC Number:
- 233-237-5
- EC Name:
- Lanthanum chloride, anhydrous
- Cas Number:
- 10099-58-8
- IUPAC Name:
- lanthanum trichloride
- Details on test material:
- - Name of test material (as cited in study report): Lanthanum chloride
- Analytical purity: no data
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River UK Ltd. (Margate, UK) or Harlan UK Ltd. (Bicester, UK).
- Weight at study initiation: 140-192 g
Administration / exposure
- Route of administration:
- intravenous
- Vehicle:
- other: sodium chloride
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Lanthanum chloride was formulated in sterile 0.9% (w/v) sodium chloride. - Duration and frequency of treatment / exposure:
- single dose
Experiment 1: 24 h exposure duration
Experiment 2: 72 h exposure duration
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Experiment 1: 0.03 mg/kg lanthanum chloride (0.017 mg/kg elemental lanthanum)
Experiment 2: 0.3 mg/kg lanthanum chloride (0.17 mg/kg elemental lanthanum)
- No. of animals per sex per dose / concentration:
- Experiment 1: two or three animals per sex, per time point (total number: n = 18)
Experiment 2: total number: n = 21 (only males) - Control animals:
- yes, concurrent vehicle
- Details on dosing and sampling:
- PHARMACOKINETIC STUDY (Absorption, distribution)
- Tissues and body fluids sampled: blood, plasma
- Time and frequency of sampling: Experiment 1: pre-dose, 15 min., 1, 2, 4, 8 and 24 h after administration; Experiment 2: pre-dose, 5, 10, 20 and 40 min., 1, 2, 4, 8, 12, 18, 24, 48, 72 h
PREPARATION
- Blood was centrifuged and plasma separated and diluted with tetramethyl ammonium hydroxide (TMAH) solution (1.25% [w/v] containing 0.1% [w/v] ethylenediaminetetraacetic acid diammonium salt [EDTA (NH4)2] as a lanthanum chelator). Lanthanum content was determined using an Agilent (Hewlett Packard) 4500 inductively coupled plasma (ICP)-mass spectrometer fitted with a Babington V-groove nebulizer and a glass spray chamber.
- The lower limit of quantification was 0.05 ng/mL. - Statistics:
- Pharmacokinetic parameters were derived from plasma lanthanum concentrations by visual inspection of the individual or mean plasma concentration curves or by non-compartmental analysis using WinNonlin® (Version 3.0, Pharsight Corporation, Mountain View, California).
The observed maximum plasma lanthanum concentration (Cmax) and the time post-dose at which Cmax occurred (Tmax) were determined by visual inspection of individual or mean plasma concentration versus time curves. The area under the plasma concentration versus time curves, calculated from time 0 to 24 h post-dose (AUC 0–24), and from time 0 to the last sample collection time (AUC last) were calculated using linear trapezoidal summation from time 0 to the appropriate time point. Total clearance (CL) following intravenous administration was calculated as Dose IV/AUC IV, and volume of distribution (Vz) was calculated as CL/k, where k was the terminal rate constant calculated following log-linear regression analysis of the linear phase of the concentration–time profile.
Results and discussion
- Preliminary studies:
- no data
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Experiment 1: AUC 0-24: 45.07 ng*h/mL (no further information given)
Experiment 2: Following intravenous injection of 0.3 mg/kg lanthanum chloride (the maximum tolerated intravenous dose established in previous studies), plasma lanthanum levels decreased rapidly from a peak of 3231±233 ng/mL measured at 5 min, to approximately 14% of Cmax by 2 h postdose. Thereafter, plasma concentrations declined at a slower rate and returned to pre-dose concentrations (3.08 ± 2.91 ng/mL) by 48 h. - Details on distribution in tissues:
- Experiment 2:
The systemic clearance of lanthanum was relatively low: 0.66 mL/(min. kg). Combined with a Vz (volume of distribution) of 1.30 L/kg that exceeded total body water (0.7 L/kg), it can be suggested that lanthanum was distributed into tissues, from where it was eliminated at a slower rate. The whole blood to plasma lanthanum ratio based on AUC last was calculated as 0.55, indicating that very little lanthanum entered or was bound to red blood cells.
- Details on excretion:
- no data
Toxicokinetic parameters
- Test no.:
- #2
- Toxicokinetic parameters:
- Cmax: 3231+/-233 mg/mL
Metabolite characterisation studies
- Metabolites identified:
- not measured
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
